Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Donepezil+ Cognitive remediation therapy · 1 trial · 1 indication
Heavy drinking days as measured by weekly Time Line Follow Back (TLFB)
| Arm | Type | Description |
|---|---|---|
| Donepezil + Cognitive remediation therapy (CRT) | EXPERIMENTAL | Subjects in this arm will receive (1) donepezil and (2) cognitive remediation therapy (CRT). Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13. |
| Donepezil + Placebo CRT | EXPERIMENTAL | Subjects in this arm will receive (1) donepezil and (2) placebo CRT. Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13. |
| Placebo medication + Cognitive remediation therapy (CRT) | EXPERIMENTAL | Subjects in this arm will receive (1) placebo medication and (2) cognitive remediation therapy (CRT). Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13. |
| Placebo medication + Placebo CRT | EXPERIMENTAL | Subjects in this arm will receive (1) placebo medication and (2) placebo CRT. Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13. |
| Name | Type | Description |
|---|---|---|
| Donepezil + Cognitive remediation therapy (CRT) | COMBINATION_PRODUCT | Subjects in this arm will receive (1) donepezil and (2) cognitive remediation therapy (CRT). Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13. |
| Donepezil + Placebo CRT | COMBINATION_PRODUCT | Subjects in this arm will receive (1) donepezil and (2) placebo CRT. Subjects will take 5 mg/day of oral donepezil in the evening for the first 4 weeks, then 10 mg/day of oral donepezil in the evening until week 13. |
| Placebo medication + Cognitive remediation therapy (CRT) | COMBINATION_PRODUCT | Subjects in this arm will receive (1) placebo medication and (2) cognitive remediation therapy (CRT). Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13. |
| Placebo medication + Placebo CRT | COMBINATION_PRODUCT | Subjects in this arm will receive (1) placebo medication and (2) placebo CRT. Subjects will take placebo oral medication in the evening for the first 4 weeks, then placebo oral medication in the evening until week 13. |
Inclusion criteria: 1. Males and females 18-80 years of age 2. Fluency in English and a 6th grade or higher reading level 3. Meets the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria for a current alcohol use disorder (subjects should have a primary alcohol use disorder \[AUD...
Donepezil+ Cognitive remediation therapy is an investigational combination being studied for Alcohol Use Disorder. It combines the small molecule donepezil with cognitive remediation therapy. The therapy is in Phase 2 clinical development and is being evaluated in a randomized, double-blind, controlled trial.
The combination therapy includes donepezil, a small molecule, paired with cognitive remediation therapy. The specific molecular target of the combination is not disclosed in the available information. The therapy is being studied for its potential effect on Alcohol Use Disorder.
Donepezil+ Cognitive remediation therapy is being developed by National Healthcare Corp., traded under the ticker NHC. The company is conducting a Phase 2 clinical trial of the combination therapy for Alcohol Use Disorder.
Donepezil+ Cognitive remediation therapy is in Phase 2 clinical development. It is an investigational therapy and has not been approved by regulatory authorities. The therapy is being studied in a randomized, double-blind, controlled trial for Alcohol Use Disorder.
Donepezil+ Cognitive remediation therapy is being evaluated in one active Phase 2 trial, NCT05042102, titled "Donepezil and Cognitive Training for Alcohol Use Disorder (AUD)." The trial is recruiting 160 participants in the United States, with an enrollment age minimum of 18 years.
Yes, Donepezil+ Cognitive remediation therapy is also known as Donepezil + Cognitive remediation therapy (CRT). Both names refer to the same investigational combination therapy being studied for Alcohol Use Disorder.